---
title: "Rinvoq (upadacitinib) in rheumatoid arthritis: Clinical trials questions"
description: "Clinical trials questions on Rinvoq (upadacitinib) in rheumatoid arthritis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: SELECT-SWITCH and SELECT-BEYOND. Questions: How was the RINVOQ vs HUMIRA SELECT-SWITCH trial designed? RINVOQ vs HUMIRA (adalimumab) in SELECT-SWITCH: what did the Week 12 comparison show? Does RINVOQ work for rheumatoid arthritis after biologic DMARDs failed or were not tolerated (SELECT-BEYOND)? What share of RINVOQ patients were in remission at 5 years (SELECT-BEYOND)? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/clinical-trials"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T01:54:55-05:00"
---

# Rinvoq (upadacitinib) in rheumatoid arthritis: Clinical trials questions

Manufacturer: AbbVie Inc.  
Prescribing information: [Rinvoq](https://www.rinvoqhcp.com/prescribinginfo)

## SELECT-SWITCH

<a id="rinvoq-switch-design"></a>

### How was the RINVOQ vs HUMIRA SELECT-SWITCH trial designed?

> “SELECT-SWITCH Study Design Intro: 12-week, randomized, double blind, head-to-head (H2H), Phase 3b/4 study that evaluated the efficacy and safety of RINVOQ (upadacitinib) + MTX versus HUMIRA (adalimumab) + MTX in 491 adult patients with moderate to severe RA who demonstrated prior failure to one non-adalimumab TNF inhibitor. Patients were randomized to receive RINVOQ 15 mg once daily + MTX or HUMIRA 40 mg every other week + MTX for 12 weeks. The primary endpoint was the proportion of patients who achieved LDA (based on DAS28-CRP ≤3.2) at Week 12. The blinded long-term extension period (Weeks 12–48) evaluated the safety, tolerability, and efficacy of RINVOQ and HUMIRA in patients with RA who completed the first part of the study.<sup>2</sup>”

Source: [RINVOQ: RINVOQ® (upadacitinib) VS HUMIRA® (adalimumab) Head-to-Head Data, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy/rinvoq-vs-humira/select-switch-study#:~:text=SELECT%2DSWITCH%20Study%20Design%20Intro%3A%2012%2Dweek%2C,the%20first%20part%20of%20the)

<a id="rinvoq-switch-long-term"></a>

### RINVOQ vs HUMIRA (adalimumab) in SELECT-SWITCH: what did the Week 12 comparison show?

> “Superior Remission* & LDA vs HUMIRA (adalimumab) at Week 12”

Source: [RINVOQ: RINVOQ® (upadacitinib) VS HUMIRA® (adalimumab) Head-to-Head Data, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy/rinvoq-vs-humira/select-switch-study#:~:text=Superior%20Remission%2A%20%26%20LDA%20vs%20HUMIRA%20%28adalimumab%29%20at%20Week%2012)

> “The primary endpoint was the proportion of patients who achieved LDA (based on DAS28-CRP ≤3.2) at Week 12.”

Source: [RINVOQ: RINVOQ® (upadacitinib) VS HUMIRA® (adalimumab) Head-to-Head Data, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy/rinvoq-vs-humira/select-switch-study#:~:text=The%20primary%20endpoint%20was%20the,DAS28%2DCRP%20%E2%89%A43.2%29%20at%20Week%2012.)

> “SELECT-SWITCH: A head-to-head study in patients with an inadequate response or intolerance to 1 TNFi evaluating RINVOQ + MTX and HUMIRA (adalimumab) + MTX with different benefit/risk profiles
>
> Remission: DAS28-CRP <2.6* (NRI-MI)
> LDA: DAS28-CRP ≤3.2 (NRI-MI)”

Source: [RINVOQ: RINVOQ® (upadacitinib) VS HUMIRA® (adalimumab) Head-to-Head Data, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy/rinvoq-vs-humira/select-switch-study#:~:text=SELECT%2DSWITCH%3A%20A%20head%2Dto%2Dhead%20study%20in,LDA%3A%20DAS28%2DCRP%20%E2%89%A43.2%20%28NRI%2DMI%29)

> “DATA LIMITATIONS: Week 48 data is a prespecified nonranked endpoint and was not controlled for multiplicity; therefore differences could represent chance findings. No conclusions regarding these comparisons can be made.”

Source: [RINVOQ: RINVOQ® (upadacitinib) VS HUMIRA® (adalimumab) Head-to-Head Data, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy/rinvoq-vs-humira/select-switch-study#:~:text=DATA%20LIMITATIONS%3A%20Week%2048%20data,these%20comparisons%20can%20be%20made.)

> “*Clinical remission does not mean drug-free remission or complete absence of disease activity.”

Source: [RINVOQ: RINVOQ® (upadacitinib) VS HUMIRA® (adalimumab) Head-to-Head Data, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy/rinvoq-vs-humira/select-switch-study#:~:text=%2AClinical%20remission%20does%20not%20mean,complete%20absence%20of%20disease%20activity.)

Note: The page states superiority at Week 12 and shows the remission and low disease activity percentages only in charts, so no rates, differences, or p-values are quoted here. The Week 48 comparison was not controlled for multiplicity.

<a id="rinvoq-select-switch-safety"></a>

### RINVOQ vs HUMIRA: what side effects were reported through Week 48 (SELECT-SWITCH)?

> “TEAE of Special Interest<sup>||</sup>	SELECT-SWITCH AEs<sup>3</sup>
> HUMIRA 40 mg
> EOW + MTX<sup>¶</sup>
>
> Week 48
>
> n=245, n (%)
> 	RINVOQ 15 mg
> QD + MTX<sup>¶</sup>
>
> Week 48
>
> n=245, n (%)
>
> INFECTIONS
> Serious infections	7 (2.9)	7 (2.9)
> Active Tuberculosis (TB)	0	0
> Opportunistic Infection (excluding TB, HZ, & oral candidiasis)	1 (0.4)	0
> Herpes Zoster (HZ)	6 (2.4)	4 (1.6)
> MALIGNANCY
> Malignancy (excluding NMSC)	3 (1.2)	1 (0.4)
> Lymphoma	0	0
> NMSC	1 (0.4)	1 (0.4)
> CARDIOVASCULAR EVENTS
> Adjudicated VTE<sup>a</sup>	1 (0.4)	2 (0.8)
> Adjudicated MACE<sup>b</sup>	1 (0.4)	1 (0.4)
> GASTROENTEROLOGICAL EVENTS
> Adjudicated GI Perforations	0	0
> LAB ABNORMALITIES
> The percentage of patients with lab-related AESIs are listed here for HUMIRA and RINVOQ, respectively: anemia (2.0, 1.6), neutropenia (1.2, 0.8), lymphopenia (0.8, 1.2), hepatic disorder (4.9, 4.5)”

Source: [RINVOQ: RINVOQ® (upadacitinib) VS HUMIRA® (adalimumab) Head-to-Head Data, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy/rinvoq-vs-humira/select-switch-study#:~:text=TEAE%20of%20Special,1.2%29%2C%20hepatic%20disorder%20%284.9%2C%204.5%29)

> “Safety rates observed in clinical trials may not predict the rates observed in clinical practice.”

Source: [RINVOQ: RINVOQ® (upadacitinib) VS HUMIRA® (adalimumab) Head-to-Head Data, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy/rinvoq-vs-humira/select-switch-study#:~:text=Safety%20rates%20observed%20in%20clinical,rates%20observed%20in%20clinical%20practice.)

> “RINVOQ requires lab monitoring for neutropenia, lymphopenia, anemia, increased lipids, and AST/ALT elevation, whereas HUMIRA does not.”

Source: [RINVOQ: RINVOQ® (upadacitinib) VS HUMIRA® (adalimumab) Head-to-Head Data, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy/rinvoq-vs-humira/select-switch-study#:~:text=RINVOQ%20requires%20lab%20monitoring%20for,elevation%2C%20whereas%20HUMIRA%20does%20not.)

> “SELECT-SWITCH was not powered or designed to evaluate safety outcomes between RINVOQ and HUMIRA. Certain adverse events may require longer observation periods and longer-term patient exposure to ascertain risk. Thus, this presentation does not mean that the risks detected in the ORAL Surveillance study would not be seen in RINVOQ.”

Source: [RINVOQ: RINVOQ® (upadacitinib) VS HUMIRA® (adalimumab) Head-to-Head Data, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy/rinvoq-vs-humira/select-switch-study#:~:text=SELECT%2DSWITCH%20was%20not%20powered%20or,not%20be%20seen%20in%20RINVOQ.)

Note: Each table row lists the HUMIRA result first and the RINVOQ result second.

## SELECT-BEYOND

<a id="rinvoq-select-beyond-efficacy"></a>

### Does RINVOQ work for rheumatoid arthritis after biologic DMARDs failed or were not tolerated (SELECT-BEYOND)?

> “NRI Data From SELECT-BEYOND (bDMARD-IR)<sup>1,7</sup>
>
> RINVOQ 15 mg + csDMARD (n=164), placebo + csDMARD (n=169)
>
>
> ACR20 | PRIMARY ENDPOINT
>
> 65%* RINVOQ vs 28% placebo at Week 12
>
> *P<0.0001 RINVOQ vs placebo.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Efficacy for Rheumatoid Arthritis, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy#:~:text=NRI%20Data%20From%20SELECT%2DBEYOND,%2AP%3C0.0001%20RINVOQ%20vs%20placebo.)

> “SELECT-BEYOND (Study RA-V)<sup>1,7</sup>:
>
> 24-week, randomized, double-blind, placebo-controlled study of 499 adult patients with moderate to severe RA who had an inadequate response or intolerance to bDMARDs. Patients on background csDMARDs were randomized to receive RINVOQ 15 mg once daily (n=164) or placebo (n=169). The primary endpoint was ACR20 response at Week 12.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Efficacy for Rheumatoid Arthritis, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy#:~:text=SELECT%2DBEYOND%20%28Study,ACR20%20response%20at%20Week%2012.)

Note: This efficacy page describes SELECT-BEYOND as a 24-week study; the rheumatoid arthritis overview page (rinvoqhcp.com/rheumatoid-arthritis) describes it as a 12-week study.

<a id="rinvoq-select-beyond-5yr-remission"></a>

### What share of RINVOQ patients were in remission at 5 years (SELECT-BEYOND)?

> “SELECT-BEYOND: bDMARD-IR patients
> ALL DATA ARE AS OBSERVED (AO)
> DAS28-CRP <2.6*
>
> 66% of RINVOQ + csDMARDs patients achieved remission at 5 years”

Source: [RINVOQ: RINVOQ® (upadacitinib) Efficacy for Rheumatoid Arthritis, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy#:~:text=SELECT%2DBEYOND%3A%20bDMARD%2DIR%20patients,achieved%20remission%20at%205%20years)

> “*Clinical remission does not mean drug-free remission or complete absence of disease activity.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Efficacy for Rheumatoid Arthritis, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy#:~:text=%2AClinical%20remission%20does%20not%20mean%20drug%2Dfree%20remission%20or%20complete%20absence%20of%20disease%20activity.,-Starting%20at%20Week)

> “Starting at Week 24, initiation of or change in corticosteroids, NSAIDs, acetaminophen, and csDMARDs was permitted. Patients not achieving response criteria ≥20% improvement in SJC and TJC at two consecutive visits were removed from the study.
>
> AO analysis: Patients with missing data at a specific time are not included, which may enrich the population and increase the response rates.
>
> LTE LIMITATIONS: There is potential for enrichment of LTE data; unblinding patients may cause bias related to overall treatment effect.”

Source: [RINVOQ: RINVOQ® (upadacitinib) Efficacy for Rheumatoid Arthritis, captured 2026-11-08](https://www.rinvoqhcp.com/rheumatoid-arthritis/efficacy#:~:text=Starting%20at%20Week%2024%2C%20initiation,related%20to%20overall%20treatment%20effect.)

## Related pages
- [Medical information: Rinvoq (upadacitinib): Rheumatoid arthritis](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis)
- [Indication](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/pharmacology)
- [Safety](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/rinvoq--rheumatoid-arthritis/access-and-coverage)
